Pfizer ends brain cancer drug development deal with Celldex

NEEDHAM, Mass. Pfizer is pulling out of a development deal for a potential brain cancer drug, saying it is not a strategic priority, according to the drug's developer Celldex Therapeutics.

Celldex said it will regain full worldwide rights to develop and sell rindopepimut from Pfizer. The drug candidate also is called CDX-110. In May, the company reported positive results form a midstage study on the drug.

Celldex will regain rights to the drug candidate on Nov. 1.